Tempest Therapeutics (NASDAQ:TPST) Given “Buy” Rating at HC Wainwright

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock.

Tempest Therapeutics Stock Performance

Shares of NASDAQ:TPST opened at $0.97 on Wednesday. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12. The firm has a market cap of $24.45 million, a price-to-earnings ratio of -0.63 and a beta of -1.78. The company’s fifty day simple moving average is $1.20 and its 200 day simple moving average is $1.96. Tempest Therapeutics has a 12 month low of $0.86 and a 12 month high of $6.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP bought a new position in Tempest Therapeutics in the second quarter valued at approximately $55,000. Virtu Financial LLC raised its holdings in shares of Tempest Therapeutics by 69.2% in the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after purchasing an additional 11,689 shares during the period. Empower Advisory Group LLC acquired a new stake in Tempest Therapeutics in the 3rd quarter valued at about $49,000. Finally, Fullcircle Wealth LLC acquired a new position in Tempest Therapeutics during the third quarter worth approximately $87,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.